



Future treatment strategy in locally advanced pancreatic cancer?

Per Pfeiffer

Professor in Clinical Oncology
Dept of Oncology, OUH, Denmark
Institute of Clinical Research, USD, Denmark



OUH
Odense Universitetshospital
Svendborg Sygehus



Pancreatic Cancer – Locally Advanced Treatment – principle – “down staging”


Resectable

Curative



Locally Advanced

Metastatic



Resectable

Chemo-Radio-Therapy (CRT)

CT

Treatment

Locally Advanced

Resectable PC

Phase III – RCT vs surgery

1999 - 2003

198 patients with resectable PC

117 patients informed, 81 registered

42 patients were randomized (150 planned)


	Surgery	RCT
	n=20	n=22
Median OS	12.1 mo*	8.9 mo
3 year survival	20%*	0%
5 year survival	10%*	0%

Imamura et al, Surgery 2004; 136: 1003-11

Doi et al, Surg Today 2008; 38: 1021-8

Resectable PC

Phase III – RCT vs surgery



No. of patients at risk

Surgery	20	13	6	4	2	2	1
Radiochemotherapy	22	8	0				



LAPC – RCT or CT ?

Phase III – RCT vs Gem

Aim: Increase 6 → 12 mo, 176 pts planned

	Gem	RCT
	n=59	n=60
Median OS, mo	13.0*	8.6
1 year survival, %	53*	32

Only 5 pts (4%) had resection




LAPC – RCT or CT ?

Phase III – RCT vs Gem



Aim: Increase 8 → 12 mo, 74/316 planned

E4201	Gem	RCT
n	36	38
Median OS, mo	9.2	11.0*



LAPC - RCT and CT ?

Non-randomised study; CT → RCT



“RCT should be offered after CT if down-staging and resection is possible”

CT in metastatic pancreatic cancer

Gemcitabine

- Anything better than gemcitabine ?



	RR	TTP	OS
Gemcitabine	10%	3 mo	6 mo

- > 10 phase III with > 4000 patients
- All "negative" except for a few studies

CT in metastatic pancreatic cancer


Gem vs GemCap

Cunningham; JCO 2009; n = 533	Gem	GemCap
	n=266	n=267
Response rate	12%	19%
Median PFS (months)	3.8	5.3
Median survival (months)	6.2	7.1



Metastatic pancreatic cancer



1st line therapy – Prodigie 4 ACCORD 11



Metastatic pancreatic cancer


1st line therapy – Prodigie 4 ACCORD 11

Conroy; ASCO 2010; n = 342	Gem	FOLFIRINOX
	n=171	n=171
Response rate	9%	32%*
Median PFS (months)	3.3	6.4*
Median survival (months)	6.8	11.1*



Locally Advanced Pancreatic Cancer

Danish experience



Locally Advanced Pancreatic Cancer

DPCG – 2010/01 – phase II

